Trial reportDigestive diseases and sciences2026
Esophageal Acid Suppression Unmasks Latent Esophageal Acid-Symptom Phenotypes in GERD.
Trial report in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-prandial esophageal acid exposure is a key determinant of symptom generation in gastroesophageal reflux disease. When esophageal acid exposure is high, high symptom intensity may mask individual variation in the relationship between acid exposure and perception.
aimsTo compare how suppression of esophageal acid by omeprazole or by ranitidine combined with antacid influences post-meal heartburn severity and to determine whether active treatment unmasks distinct esophageal acid-symptom phenotypes.
methodsTwo clinical studies used standardized meal tests in subjects with gastroesophageal reflux disease. In the omeprazole study, subjects were tested at baseline and after eight days of treatment. In the ranitidine plus antacid study, subjects were tested after placebo and active treatment in a randomized crossover design. Post-prandial esophageal acid concentration and heartburn intensity were measured for three hours (omeprazole) or four and one-half hours (ranitidine plus antacid). Total values were compared by receiver operating characteristic analysis and by quadrant classification of high and low acid-symptom relationships.
resultsBoth active treatments significantly reduced esophageal acid and heartburn intensity compared with control. Under control conditions, nearly all subjects exhibited high acid exposure with high symptom severity. Active treatment redistributed subjects across four distinct phenotypes. Discordant distributions (high-low or low-high) were similar in both trials, whereas concordant distributions differed markedly, reflecting distinct pharmacologic effects on esophageal acid-symptom coupling.
conclusionsPost-prandial suppression of esophageal acid unmasks latent esophageal acid-symptom phenotypes in gastroesophageal reflux disease. Recognition of these patterns may improve the understanding of treatment response variability and guide individualized therapy.
Indexed as
Identifiers
41563645What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.